Genus PLC

Genus PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)2,448.00
  • Today's Change-96.00 / -3.77%
  • Shares traded292.83k
  • 1 Year change-8.45%
  • Beta0.3226
Data delayed at least 20 minutes, as of Jun 05 2023 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Genus plc is a United Kingdom-based animal genetics company. It supplies breeding animals with desirable characteristics to farmers, enabling them to produce quality meat and milk. The Company's segments include Genus PIC, Genus ABS and Genus Research and Development. The Genus PIC segment is engaged in porcine sales business. The Genus ABS segment is engaged in bovine sales business. Its bovine genetics business sells dairy and beef bull semen and embryos from its superior cattle, which are sold to farmers to breed their cows through artificial insemination. Its porcine genetics business sells genetically superior breeding pigs and semen to farmers, so they can breed commercial pigs with desirable characteristics for pork production. It also provides technical services and advice to farmers, to maximize the performance of its breeding animals in their farms. It operates in over 24 countries on six continents, with research laboratories located in Madison, Wisconsin, United States.

  • Revenue in GBP (TTM)662.40m
  • Net income in GBP34.40m
  • Incorporated1994
  • Employees3.33k
  • Location
    Genus PLCMatrix House, Basing ViewBASINGSTOKE RG21 4DZUnited KingdomGBR
  • Phone+44 125 634 7100
  • Fax+44 125 647 7385
  • Websitehttps://www.genusplc.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Oxford BioMedica plc139.99m-39.16m445.17m904.00--2.17--3.18-0.4149-0.41491.482.130.40156.393.46154,855.10-12.95-4.45-15.77-5.6949.4253.90-32.26-8.163.40-3.280.3261---1.9730.08-305.97--52.60--
Ergomed PLC145.26m14.98m492.54m1.44k33.215.7623.663.390.29210.29212.831.681.23--5.30101,087.0012.738.5318.6012.5940.7241.4610.317.18--22.330.03320.0022.5024.9918.21--6.10--
Puretech Health PLC12.55m-40.45m643.86m111.00--1.54--51.32-0.1406-0.14060.04361.510.019--2.08113,032.10-4.505.21-5.586.53-----237.32265.77---2.460.07890.00-10.1843.8616.85--0.046--
Genus plc662.40m34.40m1.67bn3.33k48.532.8923.772.530.52420.524210.088.790.6899--5.76199,218.002.793.233.233.80----
Worldwide Healthcare Trust PLC-59.72m-84.06m2.00bn0.00--0.9167-----1.28-1.28-0.914935.51-0.0233-------3.287.07-3.577.52--86.92--84.78----0.0010.32-125.52---129.67----3.33
Indivior PLC761.57m-40.17m2.05bn928.00--35.38--2.69-0.3434-0.34345.340.41950.5451.504.65820,653.40-2.874.76-5.859.1183.0284.52-5.279.420.9578--0.79490.0013.91-3.79-136.59---32.56--
Hikma Pharmaceuticals Plc2.02bn151.03m4.01bn8.84k27.332.3313.101.980.66380.66388.997.790.56931.703.36228,863.304.329.135.6812.5450.2650.867.5915.511.146.700.373931.08-1.415.39-55.34--8.3010.11
Dechra Pharmaceuticals plc726.80m40.10m4.14bn2.04k101.184.9131.535.690.3590.3596.527.390.49751.676.87356,974.502.743.553.064.0057.1556.745.527.221.4011.540.377996.3512.1413.674.8617.3948.5015.93
Data as of Jun 05 2023. Currency figures normalised to Genus PLC's reporting currency: UK Pound GBX

Institutional shareholders

47.31%Per cent of shares held by top holders
HolderShares% Held
Baillie Gifford & Co.as of 01 Sep 20225.92m8.99%
Vanguard Advisers, Inc.as of 01 May 20233.65m5.55%
Threadneedle Asset Management Ltd.as of 08 Nov 20213.58m5.45%
Capital Research & Management Co. (World Investors)as of 01 Sep 20223.32m5.05%
Wellington Management Co. LLPas of 05 May 20233.12m4.75%
Devon Equity Management Ltd.as of 13 Sep 20222.67m4.07%
BlackRock Fund Advisorsas of 01 Sep 20222.44m3.70%
abrdn Investments Ltd.as of 23 May 20232.28m3.47%
The Vanguard Group, Inc.as of 01 Sep 20222.25m3.41%
Norges Bank Investment Managementas of 10 Nov 20201.89m2.87%
More ▼
Data from 31 Dec 2022 - 28 Apr 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.